Arcutis Biotherapeutics, Inc. (ARQT) is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases. With its headquarters located in Westlake Village, California, the company operates with a bold vision of applying biopharmaceutical science to dermatology for the betterment of patients’ health and quality of life.
Arcutis uses innovative technologies to accelerate the discovery and development of significant therapies for a variety of skin conditions. The company's unique approach combines an appreciation for the complexities of skin biology with insight into patients' needs. This thoughtful approach, combined with the technical sophistication and robust drug development capabilities, enables Arcutis to rapidly advance novel molecules into the clinic.
The company's portfolio is focused on immunology and inflammation. Central to this portfolio is ARQ-151 (topical roflumilast cream), an investigational nonsteroidal, once-daily, topical PDE4 inhibitor for the potential treatment of chronic skin conditions such as plaque psoriasis and atopic dermatitis. The drug is currently in Phase 3 clinical trials, with the company also planning to investigate its potential use in seborrheic dermatitis and scalp psoriasis.
In addition to ARQ-151, Arcutis is also developing ARQ-154 (topical roflumilast foam), a potential treatment for common skin disorders such as seborrheic dermatitis and scalp psoriasis, and ARQ-252, a selective JAK1 inhibitor, for hand eczema and vitiligo.
Arcutis Biotherapeutics, Inc. successfully launched its Initial Public Offering (IPO) on January 31, 2020, and currently trades under the ticker symbol ARQT on the Nasdaq Global Market. It's led by an experienced management team with a reputation for successfully pushing forward new treatments to the market and achieving high-value outcomes.
The company truly embodies its motto: 'Dermatology, reimagined'. By placing patients at the center of all operations, Arcutis genuinely believes in unlocking new opportunities to improve patients' lives. Moving forward, the company has plans to continue to leverage novel technologies to discover new molecules that will change the landscape of dermatological treatments.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends

Arcutis Biotherapeutics, Inc. announced the grant of 58,500 restricted stock units and options to purchase 17,000 shares to six new employees. These inducement grants were made under the company's 2022 Inducement Plan, with a grant date of November 2, 2026, and are subject to vesting schedules over four years, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have a ten-year term and an exercise price of $31.26 per share, matching the closing price on November 2, 2026.

Arcutis Biotherapeutics reported robust Q3 2026 financial results with net product revenues of $143.9 million, a 45% increase year-over-year, and raised its full-year revenue guidance. The company is advancing its 'Grow, Expand, and Build' strategy, including a new awareness campaign for ZORYVE with Simone Biles, and expanding ZORYVE's indications through clinical trials for moderate to severe atopic dermatitis, vitiligo, and hidradenitis suppurativa. Arcutis is also strategically deploying AI across over 30 use cases to enhance efficiency and effectiveness in various business operations.

Arcutis Biotherapeutics, Inc. (ARQT) reported Q3 earnings of $0.06 per share, significantly missing the Zacks Consensus Estimate of $0.17 per share, though revenues of $143.92 million surpassed expectations. Despite the earnings miss, the company's shares have gained 10.2% year-to-date, slightly underperforming the S&P 500. The stock currently holds a Zacks Rank #3 (Hold), indicating an expectation of performing in line with the market.